Background: Pathogenic BRCA1 and BRCA2 mutations confer a homologous recombination deficiency that underlies PARP inhibi...
...BRCA2 by DPP9 was previously shown to promote repair of DNA double-strand breaks by homologous recombination, the poly-A...
...BRCA2. GGT guides systemic therapy including PARP inhibitors, informs surgical decisions and enables cascade testing for...
...BRCA2 (BRCA1/2). Participants were randomized to receive a family communication guide with or without a 2-minute video (...
...BRCA2 gene, the most commonly selected first line treatment was combination therapy of a poly ADP-ribose polymerase (PAR...
...BRCA2, a tumor suppressor gene product, promotes HR by directly interacting with RAD51 via eight evolutionarily conserve...
...BRCA2, CHEK2, or PALB2) genes. Statistical analyses were conducted between June 2023 and March 2025. Identification of a...
...BRCA2, and other diagnostically consented core genes. We hypothesized that variants in further DNA repair genes, cryptic...
...BRCA2 and other high-penetrance gene mutations, can identify women at elevated risk, enabling proactive surveillance, ri...
...BRCA2 and ATM were the most frequently mutated genes (1.67% each), showing significant enrichment compared with all cont...
联系地址
山东省济南市章丘区文博路2号
齐鲁师范学院 genelibs生信实验室
山东省济南市高新区舜华路750号
大学科技园北区F座4单元2楼
电话： 0531-88819269
版权所有 © 2025.Genelibs 济南弘晖生物技术有限公司 鲁ICP备20007159号-2
